![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Sunday, September 25, 2022 12:34:00 PM
It’s not to say that it’s not important that top management are all at retirement age, but that a broader staffing of functions sufficient to handle the next couple years of growth be established.
Our views are not opposed but complementary imo.
The functional expansion and staffing can be addressed by different scenarios, including organic staffing or partnership/buyout, as many here are suggesting.
I think the initial GBM treatment demand can be handled since surgeries are required and assuming patients are going to select neurosurgeons in various regions/cities, this is distributed in nature.
The tumors are shipped to either Sawston initially and/or CRL Memphis if required for the Americas, which equipped with FlaskWorks units should handle initial loads and with CRL’s global footprint capacity can be incrementally added easily into existing facilities.
The advertising and sales functions don’t exist within nwbo currently, however for GBM one might assume the breakthrough only game in town nature of DCVax will not require much more than physician education and word of mouth among the doctor-patients communities. In fact, it might be better to focus on servicing GBM initially without a lot of extra inquiries about other indications.
So, I can see nwbo initially going it on their own, partnering or being bought out.
The partnership/buyout routes may allow more to be done in parallel with more boots on the ground, and thus accelerate DCVax extensions to other indications and establish a strong position of leadership in this new treatment platform.
As long as DCVax-L is approved every forward scenario is good, just how good how fast, assuming leadership is committed to advancing the DCVax platform, as it is now.
Recent NWBO News
- Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher • AllPennyStocks.com • 06/17/2024 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM